Feedback

Investigation of long-term pressure on primary packaging materials and a biologic drug product for injection with a novel autoinjector concept

ORCID
0000-0002-3569-5231
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim Germany
Primavessy, Daniel;
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim Germany
Piening, Max;
Affiliation
Springboard Pro Ltd, St. John’s Innovation Centre Cowley Road CB4 0WS Cambridge UK
Nightingale, Adam;
Affiliation
Springboard Pro Ltd, St. John’s Innovation Centre Cowley Road CB4 0WS Cambridge UK
Jameson, Heather;
Affiliation
Springboard Pro Ltd, St. John’s Innovation Centre Cowley Road CB4 0WS Cambridge UK
Latham, Matthew;
Affiliation
Springboard Pro Ltd, St. John’s Innovation Centre Cowley Road CB4 0WS Cambridge UK
Alexander, James;
ORCID
0000-0003-1168-4682
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim Germany
Büttner, Sarah;
Affiliation
Gerresheimer Regensburg GmbH Oskar-von-Miller-Strasse 6 92442 Wackersdorf Germany
Pfrang, Juergen;
Affiliation
Gerresheimer Regensburg GmbH Oskar-von-Miller-Strasse 6 92442 Wackersdorf Germany
Zapf, Andreas;
Affiliation
Springboard Pro Ltd, St. John’s Innovation Centre Cowley Road CB4 0WS Cambridge UK
Oakley, Tom;
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim Germany
Brutsche, Andreas;
ORCID
0009-0007-1457-6886
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim Germany
Saaler-Reinhardt, Sigrid

Abstract Gerresheimer and Midas Pharma have developed a novel cartridge-based autoinjector concept in which the cartridge as primary packaging is under constant pressure. In this article standard cartridge primary packaging material of five different companies were analyzed for their behavior under long-term pressure. Materials of 3 glass manufacturers and 2 manufacturers for cartridge rubber parts were considered. Within the test program septum stability, septum piercing, glide forces (GF), break-loose forces (BLF), glass breaking as well as a regulatory approved and marketed antibody drug product under pressure were subject to analysis. Under pressure the cartridge septum bulge grew within the first 14 days and then relevantly slowed down. An accelerated study in different atmospheric conditions allowed to extrapolate values for 24 months storage, not showing any signs of decay or problematic septum bulge increase. Pierce forces were in normal ranges and septum rupture could not be observed at the end of 42 days of pressurization. GF and BLF were within acceptable ranges and changes due to pressure could not be observed. Lowest glass breaking pressures at 4922 kPa turned out to be at least 3.5 times higher than pressures used in the autoinjector concept. Degradation of the Adalimumab antibody drug product due to pressure or device fluid pathway could not be observed with size exclusion chromatography, electrophoresis or sub-visible particles tested as a release testing in a GMP setting. Graphical Abstract

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © The Author(s) 2024

Use and reproduction: